(Q37865584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

Giorgio Walter Canonica

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Pascal Demoly

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Andrew H Briggs

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

Désirée E. Larenas-Linnemann

28 January 2020

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Nikolaos G Papadopoulos

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Nikolaos G Papadopoulos

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

8

S Durham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1

Jean Bousquet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

18

J Brozek

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

12

F E R Simons

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

H J Schünemann

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P J Bousquet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

C Bachert

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

T B Casale

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K-H Carlsen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

H-J Malling

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

J Anto

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

C E Baena-Cagnani

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K-C Bergmann

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

T Bieber

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M A Calderon

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

R Dahl

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Devillier

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

R Gerth van Wijk

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Howarth

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Schmid-Grendelmeier

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

G Passalacqua

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

T Zuberbier

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

18 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

765-774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21496059%20AND%20SRC:MED&resulttype=core&format=json

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Recommendations for appropriate sublingual immunotherapy clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

21 January 2018

Grazax for hay fever?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Unmet needs in severe chronic upper airway disease (SCUAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Retrospective assessment of seasonal allergic symptoms: over-rating but useful.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Validation of the classification of ARIA (allergic rhinitis and its impact on asthma).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Interpreting atmospheric pollen counts for use in clinical allergy: spatial variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Concentrations of major grass group 5 allergens in pollen grains and atmospheric particles: implications for hay fever and allergic asthma sufferers sensitized to grass pollen allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Biomolecular identification of allergenic pollen: a new perspective for aerobiological monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Recommendations for assessing patient-reported outcomes and health-related quality of life in clinical trials on allergy: a GA(2)LEN taskforce position paper.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Measuring quality of life in children with rhinoconjunctivitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

The use of quality-adjusted life-years in cost-effectiveness studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X

Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1398-9995.2011.02590.X